FINWIRES · TerminalLIVE
FINWIRES

Morgans Financial Downgrades Clinuvel Pharmaceuticals to Hold from Speculative Buy; Price Target is AU$10

By

Clinuvel Pharmaceuticals (ASX:CUV) has an average rating of overweight and mean price target of AU$19.62, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

Related Articles